By Marie Rosenthal
Earlier treatment with evolocumab (Repatha, Amgen) in adults with atherosclerosis lowered the incidence of major cardiovascular (CV) events, including death, according to a presentation made at the European Society of Cardiology, in Barcelona, Spain.
Evolocumab is the first proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) to show long-term clinical outcomes—up to 8.4 years—in patients with atherosclerotic cardiovascular disease (ASCVD).